MedPage Today on MSN

Complement Inhibitor Slowed Kidney Decline in IgA Nephropathy

Continued FDA approval of iptacopan was contingent on 2-year trial data ...
clinicaladvisor.com

Nipocalimab May Reduce NMJ Damage Without Suppressing Complement Function

Nipocalimab might lower the concentration of anti-acetylcholine receptor antibodies in people with generalized myasthenia gravis, a study shows. PHOENIX, Arizona—Nipocalimab might lower the ...

Novartis Pharma AG: Novartis IgAN data in New England Journal of Medicine show Fabhalta slowed kidney function decline by 49.3%

Fabhalta lowered likelihood of progression to kidney failure by 43% in APPLAUSE-IgAN study140.7% of patients on Fabhalta demonstrated sustained reduction of protein in urine over two years1Fabhalta gr ...
Business Wire

Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company’s investigational RNA ...

Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%

Fabhalta lowered likelihood of progression to kidney failure by 43% in APPLAUSE-IgAN study140.7% of patients on Fabhalta demonstrated sustained reduction of protein in urine over two years1Fabhalta ...